Sample size: The sample size was based on the study's primary endpoint, the change in the Western Ontario and McMaster Universities Arthritis Index (WOMAC) Pain Score (100 mm scale) from baseline through 12 weeks post-injection. Assuming that the difference in the mean responses between the Cingal and saline arms would be 10 mm, and using a 2:1 randomization ratio and significance level of 0.05 with 90% power to detect a difference, a sample size of 192 subjects (128 for Cingal and 64 for saline) was calculated. The Monovisc arm was added with the same number of patients (128) as the Cingal group. To account for a 15% drop out rate, 147 patients were planned to be enrolled in the Cingal and Monovisc groups and 74 were planned for the saline arm, for a total sample size of 368 subjects.

